natgillin/translations-raw huggingface dataset:
However, use of high-flux membranes and continuous renal replacement therapy (CRRT) increases vancomycin clearance and generally requires replacement dosing (usually after the haemodialysis session in case of intermittent haemodialysis).
Toda z uporabo visoko pretočnih membran in kontinuiranega nadomestnega zdravljenja ledvične odpovedi povečamo očistek vankomicina, kar običajno zahteva nadomestne odmerke (v primeru intermitentne hemodialize običajno po opravljeni hemodializi).
Trough values of 15-20 mg/l are usually recommended by clinical laboratories to better cover susceptible-classified pathogens with MIC ≥1 mg/L (see sections 4.4 and 5.1).
V kliničnih laboratorijih običajno priporočajo vrednosti 15-20 mg/l, da bi bolje zajeli občutljive patogene z vrednostjo MIK ≥1 mg/l (glejte poglavji 4.4 in 5.1).
PMA: post-menstrual age [(time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (post-natal age)].
PMS: pomenstrualna starost [(čas od prvega dne zadnje menstruacije do rojstva (gestacijska starost) plus čas po rojstvu (postnatalna starost)].
Intravenous administration of vancomycin is not effective for the treatment of Clostridium difficile infection.
Intravenska uporaba vankomicina ni učinkovita pri zdravljenju okužb z bakterijo Clostridium difficile.
Very rare side effects (may affect up to 1 in 10,000 people): - Sudden onset of severe allergic skin reaction with skin flaking blistering or peeling skin.
Zelo redki neželeni učinki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): - nenaden pojav hude kožne alergijske reakcije, z luščenjem kože ali pojavom mehurjev.
Anaesthetic induced myocardial depression may be enhanced by vancomycin.
Depresija miokarda, povzročena z anestetiki, se lahko pri uporabi vankomicina okrepi.
The recommended dose is 15 to 20 mg/kg of body weight every 8 to 12 h (not to exceed 2 g per dose).
Običajen odmerek je 15 do 20 mg/kg telesne mase na vsakih 8 do 12 ur (ne smemo preseči 2 g na odmerek).
Staphylococcus aureus Methicillin-resistant Staphylococcus aureus coagulase-negative Staphylococci Streptococcus spp.
Staphylococcus aureus na meticilin-odporni Staphylococcus aureus Koagulaza negativni stafilokoki Streptococcus spp.
Coagulase-negative staphylococci1 ≤ 4 mg/L
Koagulaza negativni stafilokoki 1 ≤ 4 mg/l
Vancomycin should also be avoided in patients with previous hearing loss.
Vankomicinu se moramo izogibati pri bolnikih s predhodno izgubo sluha.
In these subpopulations vancomycin serum concentration were found higher than expected in male healthy adults (see section 4.2).
Pri teh skupinah bolnikov so našli večje koncentracije vankomicina v serumu od tistih, ki so pričakovane pri zdravih odraslih moških (glejte poglavje 4.2).
In some cases, your doctor may decide to give an initial dose of up to 30 mg for each kg of body weight.
V določenih primerih vam lahko zdravnik predpiše začetni odmerek do 30 mg na kilogram telesne mase.
Species for which acquired resistance may be a problem
Vrsta s pridobljeno odpornostjo, ki lahko otežuje zdravljenje
• If you are allergic to vancomycin or any of the other ingredients of this medicine (listed in section
• Če ste alergični na vankomicin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
In patients with normal renal function, the serum concentration of vancomycin should be monitored on the second day of treatment immediately prior to the next dose.
Pri bolnikih z normalnim delovanjem ledvic je treba preveriti koncentracijo vankomicina na 2. dan terapije neposredno pred naslednjim odmerkom.
*Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours **Longer courses of oral suppression treatment with suitable antibiotics should be considered for prosthetic joint infections ***Duration and need for combination therapy is based on valve-type and organism
*Nadaljujte, dokler debridement ni več potreben, bolnik klinično napreduje ter je 48 do 72 ur brez vročine ** Pri okužbi umetnih sklepov je treba razmisliti o daljših ciklih peroralnega supresivnega zdravljenja z ustreznimi antibiotiki.
The drug is slowly bactericidal for dividing microorganisms.
Zdravilo je počasi baktericidno za mikroorganizme, ki se delijo.
In infants and older children, the volume of distribution ranges between 0.26-1.05 L/kg while clearance varies between 0.33-1.87 ml/kg/min.
Pri dojenčkih in starejših otrocih je volumen porazdelitve v razponu od 0,26 do 1,05 l/kg, vrednosti očistka pa so med 0,33 in 1,87 ml/kg/min.
PMA (weeks) Dose (mg/kg) Interval of administration (h)
PMS (tedni) Odmerek (mg/kg)
The duration of the therapy may be different depending on the individual response to treatment for every patient.
Trajanje zdravljenja je lahko drugačno pri vsakem bolniku in je odvisno od bolnikovega odziva na zdravljenje.
The greater the renal impairment, the greater the risk of developing the adverse reactions associated with the parenteral administration of vancomycin.
Večja ko je okvara ledvic, večja je nevarnost, da pride do neželenih učinkov, povezanih s parenteralno uporabo vankomicina.
Similarly, concomitant use with other medicines such as aminoglycoside antibiotics, nonsteroidal anti-inflammatory agents (NSAIDs, e.g., ibuprofen) or amphotericin B (medicine for fungal infection) can increase the risk of kidney damage and therefore more frequent blood and renal test may be necessary.
Podobno se lahko ob hkratni uporabi z drugimi zdravili, kot so aminoglikozidni antibiotiki, nesteroidna protivnetna zdravila (NSAID, npr. ibuprofen) ali amfotericin B (zdravilo za glivične okužbe), poveča tveganje za poškodbo ledvic, zato je potrebno pogostejše testiranje krvi in ledvic.
Pharmacokinetic/ Pharmacodynamic relationship
Razmerje med farmakokinetiko in farmakodinamiko
Rapid bolus administration (i.e. over several minutes) may be associated with exaggerated hypotension (including shock and, rarely, cardiac arrest), histamine like responses and maculopapular or erythematous rash (“red man's syndrome” or “red neck syndrome”).
Hitro odmerjanje bolusa (npr. v nekaj minutah) lahko povzroči izrazito hipotenzijo (vključno s šokom, in, redko, s srčnim zastojem), odzive, podobne histaminskemu, ter makulopapulozni ali eritematozni izpuščaj (»sindrom rdečega človeka« ali »sindrom rdečega vratu«).
Stevens-Johnson syndrome (SJS) has been reported with the use of vancomycin (see section 4.8).
Pri uporabi vankomicina so poročali o Stevens-Johnsonovem sindromu (SJS) (glejte poglavje 4.8).
To achieve this target when MICs are ≥ 1.0 mg/l, dosing in the upper range and high trough serum concentrations (15-20 mg/l) are required (see section 4.2).
Da bi dosegli to razmerje, če je MIK ≥ 1,0 mg/l, morajo biti odmerki v zgornjem območju in potrebne so visoke koncentracije v serumu (15-20 mg/l) (glejte poglavje 4.2).
This age group may need blood tests for controlling vancomycin levels in blood.
Zato bo pri tej starostni skupini morda potrebno spremljati raven vankomicina v krvi.
The blood concentrations of vancomycin should therefore be monitored carefully in these children.
Zato je pri takih otrocih treba skrbno spremljati koncentracijo vankomicina.
Plasma clearance is about 0.058 L/kg/h and kidney clearance about 0.048 L/kg/h.
Očistek iz plazme je okrog 0,058 l/kg/h in očistek iz ledvic okrog 0,048 l/kg/h.
Gram positive aerobic species Erysipelothrix rhusiopathiae, Heterofermentative Lactobacillus, Leuconostoc spp
Po Gramu pozitvne aerobne vrste Erysipelothrix rhusiopathiae, heterofermentativni Lactobacillus, Leuconostoc spp.
The usual duration of the therapy is 10 days but it may be different depending on the individual response to treatment for every patient.
Zdravljenje običajno traja 10 dni, vendar lahko pride do razlik v trajanju, ki so odvisne od bolnikovega odziva na zdravilo.
Vancomycin is indicated in all age groups for the treatment of the following infections (see sections 4.2, 4.4 and 5.1): - complicated skin and soft tissue infections (cSSTI) - bone and joint infections - community acquired pneumonia (CAP) - hospital acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) - infective endocarditis
Vankomicin je primeren za vse starostne skupine za zdravljenje naslednjih okužb (glejte poglavja 4.2, 4.4 in 5.1): - zapletene okužbe kože in mehkih tkiv - okužbe kosti in sklepov - zunajbolnišnična pljučnica - bolnišnična pljučnica, tudi ventilatorska pljučnica - infekcijski endokarditis
You will be given Vancomycin by medical staff while you are in hospital.
Ko boste v bolnišnici, vam bo vankomicin dajalo medicinsko osebje.
Due to ototoxicity of vancomycin therapy-adjuvant monitoring of the plasma concentrations is indicated in such cases.
Zaradi ototoksičnosti pri zdravljenju z vankomicinom je v takih primerih potrebno spremljanje koncentracije v plazmi.
Concomitant administration of vancomycin and anaesthetic agents has been associated with skin redness (erythema) and allergic reactions in children.
Hkratna uporaba vankomicina in anestetikov je pri otrocih povezana s pordelostjo kože (eritem) in alergijskimi reakcijami.
After intraperitoneal administration of 30 mg/kg serum levels of approximately 10 mg/l are reached.
Z intraperitonealnim injiciranjem vankomicina v odmerku 30 mg/kg se dosežejo serumske koncentracije približno 10 mg/l .
In patients with severe renal impairment (creatinine clearance below 20 ml/min) or those on renal replacement therapy, the appropriate timing and amount of subsequent doses largely depend on the modality of RRT and should be based on serum vancomycin trough levels and on residual renal function (see section 4.4).
Pri bolnikih s hudo okvaro ledvic (očistek kreatinina pod 20 ml/min) ali tistih na nadomestnem zdravljenje ledvične odpovedi sta pravi interval in velikost nadaljnjih odmerkov v veliki meri odvisna od načina nadomestnega zdravljenja ledvične odpovedi in morata temeljiti na najnižjih serumskih vrednostih vankomicina ter rezidualni ledvični funkciji (glejte poglavje 4.4).
In addition, it impairs the permeability of the bacterial cell membrane and RNA synthesis.
Poleg tega poslabša prepustnost bakterijske celične membrane in sintezo RNK.
At serum concentrations of vancomycin of 10 mg/l to 100 mg/l, the binding of the drug to plasma proteins is approximately 30-55%, measured by ultra-filtration.
Pri koncentracijah vankomicina v serumu 10 mg/l do 100 mg/l je vezava na beljakovine v plazmi, izmerjena z ultra-filtracijo, 30-55-%.
Also, methicillinresistant staphylococcus strains (MRSA) with reduced susceptibility for vancomycin were reported.
Poročali so tudi o proti meticilinu odpornih sevih stafilokokov (MRSA) z zmanjšano občutljivostjo na vankomicin.
Vancomycin shall only be administered as slow intravenous infusion of at least one hour duration or at a maximum rate of 10 mg/min (whichever is longer) which is sufficiently diluted (at least 100 ml per 500 mg or at least 200 ml per 1000 mg) (see section 4.4).
Vankomicin dajemo kot počasno intravensko infuzijo, ki v žilo teče vsaj eno uro, oz. z največjo hitrostjo 10 mg/min (kar o tega traja dlje), in je primerno razredčena (vsaj 100 ml za 500 mg ali vsaj 200 ml za 1000 mg) (glejte poglavje 4.4).
*The appropriate timing and amount of subsequent doses largely depends on the modality of RRT and should be based on serum vancomycin levels obtained prior to dosing and on residual renal function.
*Časovni interval in količina nadaljnjih odmerkov sta odvisna predvsem od načina nadomestnega zdravljenja ledvične odpovedi in morata temeljiti na ravni vankomicina v serumu, izmerjeni pred odmerkom, ter od rezidualne funkcije ledvic.
In patients with mild or moderate renal failure, the starting dose must not be reduced.
Pri bolnikih z blago ali zmerno okvaro ledvic začetnega odmerka ne smemo zmanjšati.
Vertigo, tinnitus, dizziness
Redki vertigo, tinitus, omotica
Acute tubular necrosis
Neznano akutna tubularna nekroza
Ototoxicity, which may be transitory or permanent (see section 4.8) has been reported in patients with prior deafness, who have received excessive intravenous doses, or who receive concomitant treatment with another ototoxic active substance such as an aminoglycoside.
O ototoksičnosti, ki je lahko prehodna ali trajna (glejte poglavje 4.8), so poročali pri bolnikih s predhodno gluhostjo, ki so dobili velike intravenske odmerke ali so se hkrati zdravili z drugimi ototoksičnimi zdravili, kot so aminoglikozidi.
Adults and adolescents (from 12 years and older) The recommended dose is 125 mg every 6 hours.
Uporaba pri odraslih in mladostnikih (starejših od 12 let) Priporočeni odmerek je 125 mg na vsakih 6 ur.
The reduced susceptibility or resistance to vancomycin in Staphylococcus is not well understood.
Vzroke za zmanjšano občutljivost oziroma povečano odpornost na vankomicin pri streptokokih slabo poznamo.
Children aged from one month to less than 12 years of age The dosage will be calculated according to your body weight.
Uporaba pri otrocih, starih več kot en mesec in mlajših od 12 let Odmerek bodo izračunali glede na vašo telesno maso.
- You have a hearing disorder, especially if you are elderly (you may need hearing tests during treatment).
- imate motnje sluha, še posebej če ste starejši (med zdravljenjem bo morda potreben preizkus sluha) - imate okvaro ledvic (med zdravljenjem boste morali na pregled krvi in ledvic).
The combination of vancomycin with an aminoglycoside antibiotic has a synergistic effect against many strains of Staphylococcus aureus, non-enterococcal group D-streptococci, enterococci and streptococci of the Viridans group.
Kombinacija vankomicina z aminoglikozidnimi antibiotiki ima sinergističen učinek proti veliko sevom Staphylococcus aureus, ne-enterokoknim streptokokom skupine D, enterokokom in streptokokom iz skupine Viridans.
Resistant > 2 mg/L 1 The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.
1 Mejne vrednosti temeljijo na vrednostih epidemiološkega praga (ECOFFs), ki loči izolate divjega tipa od tistih z zmanjšano občutljivostjo.
The drug is bactericidal for dividing microorganisms.
Zdravilo je baktericidno za mikroorganizme, ki se delijo.
The efficacy and safety of vancomycin has not been established for the intrathecal, intralumbar and intraventricular routes of administration.
Učinkovitost in varnost vankomicina pri intratekalni, intralumbalni in intraventrikularni uporabi nista dokazani.
Treatment duration with vancomycin may need to be tailored to the clinical course of individual patients.
Zdravljenje z vankomicinom je treba prilagoditi kliničnemu poteku bolezni vsakega bolnika.
These patients may be at risk for the development of adverse reactions, especially if there is a concomitant renal impairment.
Pri teh bolnikih je večja nevarnost za pojav neželenih učinkov, še posebej če imajo hkrati okvaro ledvic.
Children Vancomycin will be used with particular care in premature infants and young infants, because their kidneys are not fully developed and they may accumulare vancomycin in the blood.
Še posebej smo pozorni, kadar vankomicin dajemo nedonošenčkom in majhnim dojenčkom, saj njihove ledvice še niso povsem razvite in lahko pride do kopičenja vankomicina v krvi.
Similarly, concomitant use with nephrotoxic agents such as aminoglycoside antibiotics, NSAIDs (e.g., ibuprofen for closure of patent ductus arteriosus) or amphotericin B is associated with an increased risk of nephrotoxicity (see section 4.5) and therefore more frequent monitoring of vancomycin serum levels and renal function is indicated.
Podobno je hkratna uporaba nefrotoksičnih snovi, kot so aminoglikozidni antibiotiki, nesteroidna protivnetna zdravila (NSAID, npr. ibuprofen za zaprtje arterioznega duktusa) ali amfotericin B, povezana s povečanim tveganjem za nefrotoksičnost (glejte poglavje 4.5), zato je potrebno pogostejše spremljanje serumskih ravni vankomicina in ledvične funkcije.
Vancomycin is not usually absorbed into the blood after oral administration.
Vankomicin se pri peroralni uporabi običajno ne absorbira v kri.
The usual infusion dose is 15 to 20 mg for each kg of body weight.
Običajen odmerek je 15 do 20 mg za vsak kilogram telesne mase.
Secondary development of resistance during therapy is rare.
Pri zdravljenju redko pride do nastanka sekundarne odpornosti.
Renal dysfunction delays the excretion of vancomycin.
Ledvična disfunkcija lahko podaljša izločanje vankomicina.
The recommended vancomycin dose is 125 mg every 6 hours for 10 days for the first episode of nonsevere CDI.
Običajni odmerek vankomicina je 125 mg na vsakih 6 ur 10 dni, kadar gre za prvo epizodo CDI, ki ni huda.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see section
4.3 Kontraindikacije Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1 (glejte poglavje
Prolonged use of vancomycin may result in the overgrowth of non-susceptible organisms.
Pri dolgotrajni uporabi vankomicina lahko pride do namnožitve organizmov, ki niso občutljivi na zdravilo.
If you have an inflammatory disorder of the digestive tract (you may be at risk of side effects, especially if you also have a kidney disorder).
Če imate vnetje prebavil (lahko pride do neželenih učinkov, še posebej če imate tudi okvaro ledvic).
As vancomycin in combination with a cephalosporin may also have an antagonistic effect against some Staphylococcus epidermidis strains and in combination with rifampicin against some Staphylococcus aureus strains, preceding synergism testing is useful.
Glede na to, da ima lahko vankomicin v kombinaciji s cefalosporini tudi antagonistični učinek pri nekaterih sevih Staphylococcus epidermidis in v kombinaciji z rifampicinom pri nekaterih sevih Staphylococcus aureus, je koristno predhodno testirati sinergizem.
Pain and thrombophlebitis may occur in many patients receiving intravenous vancomycin and are occasionally severe.
Pri bolnikih, ki dobivajo vankomicin intravensko, pogosto pride do bolečin in tromboflebitisa, včasih do hudih.
The elimination half-life of vancomycin is 4 to 6 hours in patients with normal renal function and 2.2-3 hours in children.
Pri bolnikih z normalno delujočimi ledvicami je razpolovni čas izločanja vankomicina 4-6 ur in pri otrocih 2,2-3 ure.
Renal insufficiency manifested primarily by increased serum creatinine and serum urea
Pogosti ledvična insuficienca, ki se kaže predvsem s povišano koncentracijo kreatinina ali sečnine v serumu
Frequency
pogostnost
It is usually given every 8 to 12 hours.
Običajen interval med odmerki je 8 do 12 ur.
4 to 6 weeks***
4 do 6 tednov***
Neonates, infants and children less than 12 years old
Novorojenčki in otroci, stari manj kot 12 let
Continuous infusion: loading dose of 30 mg/kg followed by a maintenance dose of 1.5 mg/kg/bag in all exchanges.
Kontinuirana infuzija: začetni odmerek je 30 mg/kg, ki mu sledi vzdrževalni odmerek 1,5 mg/kg/vrečko v vseh menjavah.
In patients with multiple recurrences, consideration may be given to treat the current episode of CDI with vancomycin, 125 mg four times daily for 10 days followed by either tapering the dose, i.e., gradually decreasing it until 125 mg per day or a pulse regimen, i.e., 125-500 mg/day every 2-3 days for at least 3 weeks.
Pri bolnikih z več recidivi lahko CDI zdravimo z odmerkom vankomicina 125 mg štirikrat dnevno v obdobju 10 dni, nato sledi bodisi zmanjšanje odmerka, tj. postopno zmanjševanje odmerka do 125 mg dnevno, bodisi odmerjanje v intervalih, kjer bolniku vsaka 2-3 dni dajemo 125 do 500 mg na dan vsaj tri tedne.
In the case of patients with normal renal function, intravenous infusion of multiple doses of 1g vancomycin (15 mg/kg) for 60 minutes produces approximate average plasma concentrations of 50-60 mg/L, 20-25 mg/L and 5-10 mg/L, immediately, 2 hours and 11 hours after completing the infusion, respectively.
Pri bolnikih z normalno delujočimi ledvicami je po več intravenskih infuzijah 1g vankomicina (15 mg/kg) v trajanju 60 minut povprečna koncentracija v plazmi po koncu infundiranja 50-60 mg/l, po dveh urah 20-25 mg/l in po 11 urah 5-10 mg/l.
Nephrotoxicity has been described in children, usually in association with other nephrotoxic agents such as aminoglycosides.
Pri otrocih so opisali nefrotoksičnost, najpogosteje pri hkratni uporabi drugih nefrotoksičnih agensov, kot so aminoglikozidi.
The plasma levels obtained after multiple doses are similar to those achieved after a single dose.
Vrednosti v plazmi po več odmerkih so podobni tistim po enem odmerku.
Tell your doctor immediately if you get any sudden wheeziness, difficulty in breathing, redness on the upper part of the body, rash or itching.
Nemudoma poiščite zdravniško pomoč, če opazite naslednje znake: piskajoče dihanje, oteženo dihanje, pordelost zgornjega dela telesa, izpuščaj ali srbečico.
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:
Mejne vrednosti (MIK), ki temeljijo na testih Evropskega odbora za preskušanje za protimikrobne občutljivosti (EUCAST):
If a bullous disorder is suspected, the drug should be discontinued and specialised dermatological assessment should be carried out.
Pri sumu na bulozni dermatitis moramo takoj prekiniti zdravljenje in opraviti specializirano dermatološko oceno.
Vancomycin is poorly dialyzable by intermittent hemodialysis.
Vankomicin se med intermitentno hemodializo slabo dializira.
Tinnitus, possibly preceding onset of deafness, should be regarded as an indication to discontinue treatment.
Tinitus, ki se lahko pojavi pred izgubo sluha, je znak, da moramo zdravljenje prekiniti.
Alternative aetiologies should always be sought and Clostridium difficile enterocolitis be proven.
Vedno moramo iskati alternativne vzroke bolezni in dokazati enterokolitis, povezan z bakterijo Clostridium difficile.
Streptococcus groups A, B, C and G
Streprokoki skupin A, B, C in G ≤ 2 mg/l
Necrosis may occur after intramuscular injection.
Po intramuskularni injekciji lahko pride do nekroze.
Orientative dosing recommendations for the paediatric population are shown in table below that follow the same principles as in adult patients.
Orientacijske vrednosti za otroke so prikazane v spodnji preglednici in so izračunane po enakem sistemu kot za odrasle.
Interstitial nephritis, acute renal failure.
Redki intersticijski nefritis, akutna ledvična odpoved
Intermittent therapy: initial dose of 30 mg/kg in the long-dwell, followed by 15 mg/kg every 3-5 days during the long-dwell (the second dose should be time-based on a blood level obtained 2-4 days after the initial dose, see section 4.4).
Intermitentna terapija: začetni odmerek je 30 mg/kg in ga dodamo v raztopino dializata za menjavo, ki mu sledijo odmerki po 15 mg/kg vsake 3-5 dni v raztopino dializata za menjavo, (drugi odmerek je treba časovno določiti glede na vrednosti, dobljene 2-4 dni po prvem odmerku, glejte poglavje 4.4).
Exfoliative dermatitis, Stevens-Johnson syndrome, Lyell's syndrome, Linear IgA bullous dermatosis
Zelo redki eksfoliativni dermatitis, Stevens Johnsonov sindrom, Lyellov sindrom, s protitelesi IgA induciran bulozni dermatitis
4 to 6 weeks**
4 do 6 tednov**
In non-inflamed meninges, vancomycin passes the blood-brain barrier only to a low extent.
Če možganska ovojnica ni vneta, vankomicin samo v majhni meri prehaja skozi krvno-možgansko pregrado.
Intravenous administration
Intravenska uporaba
Oral Administration Patients aged 12 years and older
Peroralna uporaba Bolniki, stari 12 let ali več
Bone and joint infections
Okužbe kosti in sklepov
Very rare
Redko vaskulitis
Development of Drug-Resistant Bacteria
Razvoj bakterij, odpornih na zdravilo
The recommended vancomycin dose is 10 mg/kg orally every 6 hours for 10 days.
Priporočeni odmerek vankomicina je 10 mg/kg telesne mase na vsakih 6 ur.
Therefore, the below mentioned adverse reactions and frequencies related to parenteral vancomycin administration are included.
Zato so spodaj navedeni neželeni učinki in njihova pogostnost pojavljanja pri parenteralni uporabi vankomicina.